Background. High cardiovascular risk in chronic kidney disease (CKD) patients appears only partly attributable to atherosclerosis, with much of the remaining risk being ascribed to other vasculature abnormalities, including endothelial dysfunction, arterial stiffness and vascular calcification (VC). To date, these factors have been primarily studied in isolation or in dialysis patients. This study performed a global vascular assessment in moderate CKD and assessed the relationships with both traditional and novel risk factors. Methods. This was a prospective cross-sectional analysis of 120 patients (age 60 6 10 years; estimated glomerular filtration rate 25-60 mL/min/1.73m 2 ). Demographic, clinical and biochemical characterization was performed. VC was characterized by lateral lumbar radiograph; arterial stiffness by aortic pulse-wave velocity (PWV); atheroma burden by carotid intima-media thickness (cIMT) and endothelial function by flow-mediated dilation (FMD) of the brachial artery. Results. VC was highly prevalent (74%), and FMD generally poor (FMDD 3.3 6 3.3%). There were significant correlations between all vascular parameters; although these were predominantly explained by age. cIMT was independently associated with classical risks and also PWV (adjusted standardized b ¼ 0.31, P ¼ 0.001). However, traditional risks showed almost no independent associations with other vascular measurements. In contrast, serum phosphate and 1,25-dihydroxyvitamin D (1,25-OHD) correlated with PWV and the presence of VC, respectively. After adjustment, every 1 pg/mL increase in 1,25-OHD was related to a 3% reduction in the chance of VC (odds ratio 0.97; 95% confidence interval 0.94-1.00, P ¼ 0.03). Medication use, HOMA-IR and C-reactive protein did not correlate with any of the vascular measures. Conclusions. This study demonstrates extensive vascular disease across multimodality imaging in moderate CKD. Atherosclerotic burden correlated with traditional risks and PWV, while higher 1,25-OHD was associated with less VC. The lack of association between renal function and imaging indices raises the possibility of a threshold, rather than graded uraemic effect on vascular health that warrants further exploration.
Introduction
There is a high burden of cardiovascular (CV) events amongst chronic kidney disease (CKD) patients [1] . Traditional Framingham risk factors are independent predictors of increased CV risk in CKD, but only account for a portion of this heightened risk [2] . Moreover, interventions in CKD patients targeting these factors have generally not proved to be effective at ameliorating CV risk when examined in randomized controlled trials [1, [3] [4] [5] , with the notable exception of cholesterol-lowering therapy in the SHARP trial [6] . Therefore, it appears that atherosclerosis only accounts for part of the mortality risk.
As CKD advances, various metabolic abnormalities occur which predispose to vascular transformation, a process which includes atherogenesis, increased arterial stiffness, vascular calcification (VC) and endothelial dysfunction [7, 8] . These phenotypic changes have been correlated with CV outcomes in CKD [9] , and although once considered a result of the uraemic 'milieu', it is now postulated that these changes in themselves may form part of the causative pathway leading to the increased CV event rate of this population.
However, to date, vascular, structural and functional parameters have been assessed in isolation or in end-stage kidney disease, where factors associated with renal replacement therapy may in themselves have a confounding effect and where advanced vascular changes may be irreversible. Vascular stiffness is associated with (and likely a result of) VC in advanced CKD [10, 11] , although only one trial to date has been performed in pre-dialysis patients that assessed arterial stiffness in the same vessel in which calcification was assessed [12] . Furthermore, it is presently uncertain whether arterial stiffness and VC correlate with atheroma burden [measured as carotid intima-media thickness (cIMT)] or endothelial function [brachial artery reactivity (BAR) with flow-mediated dilation (FMD)] early in the course of CKD and whether they are associated with traditional and/or non-traditional CV risk factors.
The current study aims to undertake a global assessment of vascular parameters in patients with Stages 3-4 CKD and assess the relationship between these measurements, traditional CV risks and some of the novel CV risk factors associated with CKD that have been implicated in the genesis of the vascular disease (particularly indices of bonemineral homeostasis, inflammation and insulin resistance).
Materials and methods

Study design, participants and setting
A prospective, cross-sectional, observational study was undertaken in adult patients with Stages Further details of the trial can be found at www.anzctr.org.au.
Enrolled patients had to have at least one modifiable risk factor (hypertension, elevated body mass index, elevated HbA1c or abnormal lipid profile) that was above the therapeutic target range. Major exclusion criteria included anticipated death or dialysis within 6 months, solid organ transplant recipients, pregnancy and enrolment in other studies. All patients provided written informed consent, and the study was performed in line with the Declaration of Helsinki. The study was approved by the ethics committee of Princess Alexandra Hospital (HREC 2007/190 ) and registered at the Australian and New Zealand Clinical Trials Registry (ACTRN12608000337370).
Data collection
Demographic and clinical data were collected at the baseline assessment. Smoking history was calculated as the product of smoking frequency (cigarette packets/day) and duration (one pack of 20 cigarettes/day for 1 year ¼ one pack year). Drug history, including prescribed and overthe-counter medications, was recorded. Use but not dose of active vitamin D supplements (all calcitriol), calcium supplements and phosphate binders (all calcium based) were collected. Framingham 10-year risk was calculated using gender-specific scores and was based on age, diabetic and smoking status, total and high-density lipoprotein (HDL) cholesterol and systolic blood pressure (SBP) [13] .
SBP and diastolic blood pressure (DBP) were measured after 5 min rest, using an automated device (BPM-300; VSM MedTech, Vancouver, Canada). The average of three readings taken at 1 min intervals was used for analysis. Mean arterial pressure was calculated as (2 3 DBP 1 SBP)/ 3. Pulse pressure (PP) was calculated as SBP-DBP.
Biochemical measurement
Venous blood and a spot urine sample were collected after a 10-h overnight fast. Haemoglobin, creatinine, calcium, phosphate, glucose, insulin, lipid profile, parathyroid hormone, C-reactive protein (CRP) and urinary protein and creatinine were measured using standard automated laboratory techniques. Serum 25-hydroxyvitamin D (25-OHD) was measured using UPLC with dual mass spectroscopy (CoV 7.6% at 30.4 ng/mL, lower limit of detection <0.8 ng/mL; Nihon Waters K.K., Tokyo, Japan). 1,25-Dihydroxyvitamin D (1,25-OHD) by radioimmunoassay (CoV 15.9% at 26.5 pg/mL, lower limit of detection <3.8 pg/mL; Diasorin S.p.A., Vercelli, Italy).
Calcium was corrected for albumin [total calciumÀ(albumin (g/L) À40) 0.02]. Insulin resistance was quantified using the homeostatic model assessment (HOMA-IR), calculated as (fasting glucose 3 fasting insulin)/405 [14] . Vitamin D status was categorized by serum 25-OHD levels as per K/DOQI guidelines [15] .
Glomerular filtration rate (GFR) was determined using the Modification of Diet in Renal Disease-175 formula [16] ; CKD stage was defined as per K/DOQI guidelines [17] (with subdivision of Stage 3 to 3a/b as per KDIGO controversies conference [18] ). Due to recent concern regarding limited precision and underestimation of GFR at higher values by the MDRD formula, renal function was also calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula [19] , which has been shown to better correlate with prevalent CV disease burden [20] . Additionally, to ensure that the target population specifically included patients with intrinsic renal disease, repeat subgroup analysis was performed in only those patients with significant proteinuria (urinary protein:creatinine ratio !442 mg/g).
Vascular parameters
All vascular measurements were performed in a temperature-controlled room (24 AE 1°C).
cIMT was used to assess atheroma burden [21] . Longitudinal images of the extracranial carotid arteries were acquired using a 12 MHz linear probe (Philips IE33, Andover, MA) in three imaging planes. The digital cine-loops, consisting of two complete cardiac cycles, were measured on the R wave of the ECG using automated edge tracking software (IMT plug-in, QLab; Philips Medical Imaging, Andover, MA). cIMT was averaged from the six measurements. Intraobserver variation were 0.01 AE 0.04 mm (CoV 5%).
Endothelial function was assessed using BAR-flow-mediated vasodilation (FMD) [22] . Patients were studied in the fasted state, and specifically prohibited from smoking or imbibing caffeinated products before the study. Vasoactive medications were withheld for 24 h prior. After lying recumbent for 5 min, longitudinal cine-loops of the brachial artery were acquired above the antecubital fossa using a 12 MHz ultrasound probe (Philips IE33). Subsequently, a pneumatic cuff was inflated to 250 mmHg on the ipsilateral forearm for 4 min. Images were reacquired at the beginning and 60 s after cuff deflation to obtain hyperaemic response. After 15 min rest, resting imaging was repeated and the patient administered 400 lg of sublingual glyceryl trinitrate (GTN), with further imaging 3 min thereafter, to assess endothelial-independent vasodilation (BAR-GTN). All measurements were performed according to the American Society of Echocardiography recommendations [23] , using an average of three point-to-point measurements (Connected Care Viewer; Kardia Health Systems, Golden Valley, MN). Both BAR-FMD and BAR-GTN were expressed as percentage change from resting (%D). Intraobserver variation for BAR-FMD was 1 AE 4% (CoV 5%).
VC was quantified by abdominal aortic calcification (AAC) score on lateral lumbar radiograph [24] . Standing lateral lumbar radiographs were obtained (100 cm film distance, 94 KVP, 33-200 mAs), and both the presence and extent of calcification on the anterior and posterior walls of the aorta between L1-L4 were assessed by a single consultant radiologist. Each lumbar segment could be allocated a maximum score of 6 (three per wall, depending on extent of calcification), with a total maximum score of 24.
Arterial stiffness was assessed using carotid-femoral aortic pulse-wave velocity (PWV) [25] . Pressure waveforms at the carotid and femoral artery were captured using applanation tonometry (Sphygmacor BPAS-1; AtCor Medical, Sydney, Australia). The distance between the two sites was recorded, and wave transit time calculated by the software, using the foot-to-foot method [26] and the R wave from simultaneous ECG recording as a reference frame, over a 10-s period. An inbuilt quality control monitor [operator index, (OI)] allowed real-time assessment of the adequacy of recordings, and only high quality (OI > 90%) traces were used. An average of three recordings was used for analysis; intraobserver variability was 0.08 AE 0.80 m/s (CoV 7%).
Statistical analysis
Data distributions were assessed using the Shapiro-Wilks test. As Framingham 10-year risk scores have an upper limit defined as >30% risk, the data were transformed into quartiles for analysis. Data were expressed as mean AE standard deviation for normally distributed (ND) variables, median (interquartile range) for non-normally distributed (NND) data and as proportions (%) for categorical variables. Group means were compared by student's t-test for ND data or by Mann-Whitney U-test for NND data. Comparison of means across more than two groups was performed by one-way analysis of variance (ANOVA) or by Kruskal-Wallis test if not ND. Categorical data were analysed by Pearson's chi squared or Fisher's exact test, as appropriate. Associations between continuous variables were assessed by Spearman's rank correlation. Linear (ordinal least squares) and logistic regression were performed, as appropriate, with transformation to normalize the dependent variable, if necessary. Multivariable models were constructed using backwards stepwise regression, with factors included if P 0.1 in univariate analysis. Analysis was by available data, with casewise deletion if data was missing from individual analyses. All statistical analysis was performed using Stata SE 11.1 (Statacorp, College Station, TX). Significance was set at P < 0.05.
Results
Patient characteristics
120 patients were included in the analysis. Complete data were available for cIMT, FMD, PWV and AAC in 112, 108, 103 and 61 patients, respectively. AAC assessment was added as an amendment to the original protocol and therefore fewer patients had these scans performed. The characteristics of the cohort are depicted in Table 1 . By Framingham risk stratification, 41 (34%) patients had a 10-year CV event risk of >30%.
Vascular parameters
There was significant correlation between the vascular parameters measured, detailed in Table 2 . Notably, flow-mediated vasodilation (BAR-FMD) was minimal, with a mean change from rest of 3.3 AE 3.3%. This demonstrated significant endothelial dysfunction, when endothelial-independent vasodilation was considered, with the use of GTN (BAR-GTN) causing a median vessel calibre change from baseline of 11.7% (6.7-15.9).
Of those patients scanned, 74% had evidence of abdominal aortic VC. Those patients with VC had higher PWV (10.2 versus 8 m/s, P ¼ 0.03), the extent of calcification showing a trend to positive correlation with PWV (rho ¼ 0.25, P ¼ 0.08).
Renal function and vascular measures
Calculating renal function using the CKD-EPI formula, in 75 patients, the estimated glomerular filtration rate (eGFR) increased (mean increase 2.5 AE 2.2 mL/min/1.73m 2 , maximum increase 12 mL/min/1.73m 2 ) and in 31 patients eGFR decreased (mean decrease À1 AE 0.8 mL/min/1.73m 2 , maximum decrease À4 mL/min/1.73m 2 ). This resulted in the CKD stage being reclassified in 11 patients (four, Stage 4 to Stage 3; six, Stage 3 to Stage 2 and one Stage 3 to Stage 4). Correlation analyses were run for both formulae with the vascular parameters of interest, as total groups and restricted to those only with significant proteinuria.
Neither the presence or extent of VC, cIMT, PWV or BAR-FMD were associated with any measure of renal function (data not shown). Acknowledging the bias and confounding that could occur from the presence of diabetes, the analysis was rerun with only non-diabetics (n ¼ 66), and the only parameter that was significantly associated with eGFR was BAR-FMD (rho À0.28, p ¼ 0.03 (MDRD), 0.04 (CKD-EPI)), the association of which was lost when restricted to only those with significant proteinuria. As such, given the relatively limited range of BAR-FMD observed and the small number in the subanalysis, it was felt that this was a statistical (Type 1) anomaly and not a true finding. Table 3 details the relationship between vascular measures and both traditional and non-traditional CV risk factors. Age and SBP were major correlates with almost all indices of vascular structure or function, but only age remained an independent predictor of these after adjustment for confounding. With the exception of BAR, all vascular parameters progressed in a detrimental manner (increased PWV, VC, cIMT) across quartiles of Framingham risk scores (P < 0.005 for all trends; Figure 1A-D) . Despite this, no class of anti-hypertensive agent, statin use or anti-platelet therapy was significantly associated with the vascular hallmarks measured. Diabetics exhibited higher PWV (10.2 versus 8.9 m/s, P ¼ 0.01), VC (88 versus 64%, P ¼ 0.04) and lower BAR-GTND (8.7 versus 13.5%, P ¼ 0.004). Insulin resistance (HOMA-IR) and inflammatory burden (CRP) did not correlate with any of the vascular parameters measured in the current study.
Associations of vascular parameters with CV risk factors
Neither corrected nor ionized calcium correlated with any measured aspect of the vasculature, whereas serum phosphate was associated with PWV (standardized b ¼ 0.21, P ¼ 0.04), as was calcium-phosphate product (standardized b ¼ 0.20, P ¼ 0.05). However, neither phosphate nor calcium-phosphate product correlated with either the presence or extent of VC. Moreover, neither exogenous calcium intake (supplements or as phosphate binders) nor active vitamin D supplements correlated with vessel structure or function.
25-OHD status was not related to vascular markers in the current study. Mean 25-OHD was 33 AE 13 ng/mL, with 50 patients (42%) being insufficient and only 8 (7%) patients were frankly deficient, according to K/DOQI guidelines.
Active 1,25-OHD concentrations were lower in patients with VC (33 AE 19 versus 41 AE 14 pg/mL, P ¼ 0.05). 1,25-OHD was the only bone-mineral parameter that remained a significant predictor of VC after adjustment for confounding, with every 1 pg/mL increase in 1,25-OHD being associated with a 3% risk reduction of VC (odds ratio 0.97; 95% confidence interval 0.94-1.00, P ¼ 0.03).
Not surprisingly, increased cIMT demonstrated significant associations with traditional CV risks. In multivariable regression, the independent predictors of increased cIMT were older age, male sex, PWV and a greater cumulative smoking history (pack years), explaining almost 40% of the variation seen (adjusted R 2 ¼ 0.38, P < 0.001). The addition of PWV accounted for almost 20% of the explanatory power in this model (semipartial R 2 ¼ 0.07, P < 0.001).
Building multivariable models to predict vascular parameters other than cIMT proved difficult as a result of the confounding effects of age. Adjustment for age resulted in both loss of significance of many parameters and models with limited explanatory power.
Discussion
This is the largest study to date of pre-dialysis CKD patients using multimodality vascular imaging to characterize the structure, function and calcification of vessels. The key findings were that vascular changes were well established in moderate CKD, were correlated with each other, but with few CV risk factors other than age and 1,25-OHD. Importantly, no correlation was observed between vascular changes and the severity of CKD over the range of observed eGFR values.
The average FMD and cIMT measurements in the current study were similar to those observed in a previous study by our group, which assessed both Stage 5D CKD patients and a cohort of patients with diagnosed significant coronary artery disease but normal renal function [27] . VC appeared also to be established early in our cohort of moderate CKD patients, with our prevalence data being comparable to those observed in another study [28] . Additionally, arterial stiffness was abnormal with our results correlating well with the largest study of PWV in predialysis CKD to date (CRIC ancillary study) [29] . Indeed, using the cut-off defined as the lowest value of the highest tertile of CV risk (>10.2 m/s), 40% (41/103) of the current study participants would have been classified at highest risk by PWV alone.
Although there was significant agreement between the various vascular imaging techniques utilized, this was predominantly explained by their coexistence and individual significant relationships with advancing age. Interestingly, the only correlation that persisted after adjustment for ageing was the independent corroboration between cIMT and PWV. This highlights an important area that requires further study; i.e. whether atheroma causes increased vessel stiffness or whether shear stress and transmitted pressure from increased PWV causes atherosclerotic disease or the two processes may just coexist in individuals at high vascular risk. Interestingly, in terms of risk, Zoungas et al. [30] have previously found that PWV but not cIMT was predictive of composite CV (primarily atherosclerotic) events in prevalent patients with CKD Stages 4-5 after adjustment for confounding. This may imply that while cIMT indicates the presence and extent of atherosclerosis, the relative risk of rupture, occlusion or critical stenosis in atheromatous plaques may be more attributable to arterial stiffness and haemodynamic interaction.
cIMT is a hallmark of atheromatous disease and is clearly affected by classical Framingham risks (age, gender, smoking history, SBP, and HDL cholesterol). This is in keeping with the previous observations of London et al. [31] in the haemodialysis population, and as observed previously is dictated more by these factors than any uraemic effect per se [32] . However, despite an agreement existing between the other vascular parameters and the Framingham risk score (a composite of the variables noted plus diabetes), only SBP, PP and diabetes showed consistent correlation across the measurements taken, and except for SBP and FMD, there was no independent predictive relationship between these factors and the vascular hallmarks, when adjusted in multivariate regression. This highlights the need to consider the possibility that while each vascular parameter can aid in risk stratification, the underlying pathology that each technique represents may be divergent.
Much attention has been given to VC in the renal literature over the last decade, both in terms of cause of, and mitigation by prescribed medication in the treatment of CKD mineral and bone disorders (CKD-MBD). In the current study, no significant effect of either exogenous calcium compounds (supplements or as phosphate binders) or active vitamin D supplementation was detected on the calcific process, despite current guidelines advocating avoidance or limited use of such products if calcification is present [33] and previous work that has suggested a relationship between VC and active vitamin D use [34] .
Our findings are also in agreement with previous studies that have failed to identify a significant association between VC and active vitamin D use [35] [36] [37] . It is worth noting in the current study that there was an association between the presence of calcification and lower circulating 1,25-OHD levels. Similar associations have been reported previously in both non-renal [38, 39] and CKD populations [36] .
Experimental models have demonstrated that 1,25-OHD could inhibit VC via mechanisms such as up-regulation of calcific inhibitors (e.g. matrix Gla protein) [40] or by inhibiting the cell-signalling process that promotes osteoblastic phenotypic change in vascular smooth muscle cells (VSMCs) [41, 42] . The lack of association between vascular parameters and 25-OHD may be explained by the high prevalence of 25-OHD sufficiency in our cohort. Previous reports in the literature have been inconsistent with some studies reporting a correlation between VC and 25-OHD [37, 43] and others not [35] . Those that report an association generally had lower 25-OHD values in their cohorts (mean~21.6 ng/mL), whereas studies demonstrating no relationship were typically characterized by routine nutritional vitamin D supplementation and supraphysiological serum 25-OHD levels (~43.3-49.7 ng/mL) [35] . We hypothesize that in states of sufficiency, the relative effects of 1,25-OHD will be orchestrated by renally produced, circulating 1,25-OHD, which is homeostatically maintained by mechanisms irrespective of 25-OHD levels; this concept is supported by the relatively weak relationship between 25-OHD and 1,25-OHD in this study (r 2 ¼ 0.09, P < 0.001). Only in states of vitamin D deficiency or loss of activating 1a-hydroxylase (CYP27B1) activity in the kidneys (advanced CKD) would tissues rely on auto-or paracrine production of 1,25-OHD (from intrinsic CYP27B1 activity, which VSMCs possess [44] ), that would not be reflected in the circulating 1,25-OHD but would correlate with substrate availability for this process (25-OHD).
Lastly, it is noteworthy that none of the vascular indices measured correlated with renal function. While several studies have demonstrated a relationship between renal function and arterial stiffness [29, [45] [46] [47] [48] , these studies generally cover a wide range of eGFR from normal (<100 mL/min/ 1.73m 2 ) to Stage 5D and, on occasion, amalgamate the control population in the regression analysis. Within an individual stage of moderate CKD, the correlation is less robust, highlighted by the work of Wang et al. [45] , who reported a stepwise increase in arterial stiffness with CKD stage, although found no difference in PWV at CKD Stage 3 (10 m/s), and Stage 4 (10.3 m/s). These results are similar to the findings of Brie et al. [46] , when their analysis of renal function and PWV was restricted to CKD Stages 3-5. These results suggest that arterial stiffness changes early in CKD and is increased compared to healthy [49] or even hypertensive populations [46] . The parameters may not increase appreciably thereafter throughout the pre-dialysis stages of CKD, although may be further affected by dialysis, an event known to accelerate VC, inflammatory burden and other factors thought to influence arterial stiffness [8, 50, 51] . Thus, fitting a line of best fit for regression of arterial stiffness works across a spectrum from health to severe disease but not in intervening isolated cohorts. Indeed, given the greater chance of a CV event than progression to ESKD, it may be that significant changes occur early in CKD, but the individual disease trajectories are not parallel in extent or severity. Moreover, it is conceivable that a state of 'coexistence' is established early in the natural history of CKD when a uraemic 'threshold' is crossed.
In a similar fashion, endothelial-dependent vasodilation appeared to change and deteriorate early, with little change thereafter through advancing stages of CKD. In our study, the relative change in vessel calibre in response to flowmediated shear stress was impaired in Stage 3a CKD and comparable to figures obtained in the dialysis population [11, 27] . As such, while endothelial dysfunction was predictive of future CV events [52] , it may be that the determining factors that adversely affect endothelial health occur early. In the current study, we were unable to determine major explanatory variables in this process, and while atherosclerosis and inflammation have been associated with endothelial dysfunction [53] , we were unable to demonstrate this link.
The principal limitation of our study was that there were a relatively small number of patients over a restricted range of renal function, which could have potentially limited our ability to detect significant associations, thereby leading to a Type 2 statistical error. However, to date, this is the largest (and only) study of its kind. Additionally, the estimation of renal function using creatinine-based formulae is somewhat controversial, and the most appropriate way of assessing milder renal impairment is subject to debate. While the use of alternate markers such as cystatin C may have a role in the future, the use of calculated eGFR is widespread, practical and allows ready comparison between studies. Analysis of our cohort demonstrated that 85% had additional evidence of renal damage (ultrasound anomalies, albuminuria or haematuria), and thus, we are confident that the majority of patients in the study defined as having renal impairment by eGFR was accurate. Additionally, the fact that analysis by two different eGFR methods together with restriction of the analysis to only those patients with significant proteinuria did not alter the correlation analyses between vascular parameters and renal function gives us confidence that the negative finding is correct.
The participants were selected for modifiable CV risk factors and were notably predominately overweight or obese. However, it could be argued that this is precisely the group that needs close scrutiny of the underlying pathophysiology of CV risk. The study was cross-sectional in nature and thus causality cannot be inferred. VC was highly prevalent, although the extent of calcification may have been under-estimated using plain x-ray and a limited scoring system that correlates well with CV risk, but possibly lacked precision in profiling calcific burden in the vessel of interest. Additionally, VC was measured in only 51% of the study cohort, and hence associative parameters for this aspect of vascular structure should be interpreted cautiously. While we observed that the risks of abnormal vascular indices were divergent from traditional Framingham risks (with the exception of cIMT), the possibility of a common causative factor that was not measured in the current study cannot be excluded.
In summary, this is the first large study examining multimodal vascular imaging in Stages 3-4 CKD and demonstrates a high prevalence of abnormalities of vascular structure, function and calcification, which were principally associated with advancing age. A higher prevalence of VC was associated with lower serum 1,25-OHD levels but not with indices of bone-mineral homeostasis, subclinical insulin resistance or inflammation. Importantly, there was no appreciable effect of renal function on vascular health over the range of renal function observed, leading us to hypothesize that there may be a threshold, rather than graded effect of negative uraemic consequence on vascular health that warrants further examination.
